Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Drug Development: Seeing Light In The Dark Ages?

This article was originally published in Start Up

Executive Summary

Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.

You may also be interested in...



Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

Orexigen halts Contrave development for U.S., but the firm will appeal the division's "unprecedented" trial request through FDA's dispute resolution process.

Omthera Pharmaceuticals Inc.

Omthera Pharmaceuticals is betting that its so-called "free" fatty acid form of omega-3 will prove superior to other companies' ethyl esther versions at reducing blood triglyceride levels. An ethyl ester is a free fatty acid with an ethanol bond on it; that bond is broken in the intestines by pancreatic lipase, an enzyme specialized in breaking down fat. In Omthera's version of omega-3 fatty acid, that bond is broken already. The company thinks the difference will allow the free form to more effectively reduce TGL levels.

Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes

DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel